Comparison
21q22 11q22 12 Microdeletion Syndrome C5192593 vs 16p12 1p12 3 Triplication Syndrome C5680097
Clinical comparison between 21q22 11q22 12 Microdeletion Syndrome and 16p12 1p12 3 Triplication Syndrome for differential diagnosis and treatment planning.
21q22 11q22 12 Microdeletion Syndrome C5192593
A rare genetic condition involving deletion of a specific region on chromosome 21. It may cause developmental delay, intellectual disability, and distinctive facial features. Management focuses on developmental support and medical monitoring.
16p12 1p12 3 Triplication Syndrome C5680097
An extremely rare chromosomal disorder involving three copies of genetic material on chromosome 16. Limited cases are reported, and features may include developmental delays and physical differences. Care is individualized based on specific needs.
6 comparison axes
Onset
21q22 11q22 12 Microdeletion Syndrome C5192593
0-0
16p12 1p12 3 Triplication Syndrome C5680097
0-null
Onset patterns differ
Severity
21q22 11q22 12 Microdeletion Syndrome C5192593
severe
16p12 1p12 3 Triplication Syndrome C5680097
moderate
Different severity levels
Chronic
21q22 11q22 12 Microdeletion Syndrome C5192593
Chronic
16p12 1p12 3 Triplication Syndrome C5680097
Chronic
Differing course
Communicable
21q22 11q22 12 Microdeletion Syndrome C5192593
No
16p12 1p12 3 Triplication Syndrome C5680097
No
Different transmission
Body System
21q22 11q22 12 Microdeletion Syndrome C5192593
congenital
16p12 1p12 3 Triplication Syndrome C5680097
congenital
Same/different system
Category
21q22 11q22 12 Microdeletion Syndrome C5192593
rare-disease
16p12 1p12 3 Triplication Syndrome C5680097
genetic
Different category
Bottom line
21q22-11q22-12-microdeletion-syndrome-C5192593 and 16p12-1p12-3-triplication-syndrome-C5680097 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 16p12 1p12 3 Triplication Syndrome C5680097 | Discriminating power |
|---|---|---|---|
| Developmental delay | Described as possible, with intellectual disability also reported. | May occur, but the range is not established from sparse reports. | Low |
| Physical differences | Distinctive facial features are described. | Physical differences may occur, without a defined pattern here. | Low |
| Severity label | Supplied severity is severe, though individual course varies. | Supplied severity is moderate, based on limited evidence. | Moderate |
When to favor each condition
Choose 21q22 11q22 12 Microdeletion Syndrome C5192593 when
A deletion involving the named chromosome 21 region is confirmed.
The diagnosis depends on the specific missing segment, not shared developmental features.
High
Intellectual disability and distinctive facial features accompany the deletion.
These features are mentioned for the left condition, but are not definitive alone.
Moderate
Congenital onset is documented.
The supplied onset is at birth, while the right onset is not established.
Moderate
Choose 16p12 1p12 3 Triplication Syndrome C5680097 when
Testing shows three copies of the named chromosome 16 region.
Triplication, rather than deletion, defines the right condition.
High
Only sparse case information is available.
The source states that reported cases are extremely limited.
High
Developmental delay or physical differences lack a chromosome 21 deletion.
These nonspecific findings require chromosomal confirmation before assignment.
Moderate
How key tests differ
| Test | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 16p12 1p12 3 Triplication Syndrome C5680097 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect loss of the specified chromosome 21 region. | May detect gain consistent with three copies of the specified chromosome 16 region. | Copy-number result distinguishes deletion from triplication; clinician and laboratory confirmation is required. |
| Karyotype | May be normal if the deletion is below its resolution. | May miss a small triplication. | A normal karyotype does not exclude either condition. |
| Targeted confirmation | Confirms the chromosome 21 deletion when appropriately designed. | Confirms extra chromosome 16 material when appropriately designed. | The exact method and interpretation belong to the genetics laboratory. |
Prognosis comparison
21q22 11q22 12 Microdeletion Syndrome C5192593
- Outcome
- A severe, chronic congenital course is suggested, but individual prognosis is not quantified.
- Factors
- Confirmed deletion, developmental findings, and associated medical needs.
16p12 1p12 3 Triplication Syndrome C5680097
- Outcome
- A moderate chronic course is labeled, but outcomes are uncertain because cases are extremely limited.
- Factors
- Confirmed triplication and each person's developmental and physical findings.
Time frame: Lifelong, with congenital recognition for the left and unspecified onset for the right.
No mortality, prevalence, or exact outcome estimates are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental needs | Support for delay and intellectual disability may be needed. Developmental support may be needed, but needs are not fully characterized. No complication rates are established in the supplied data. |
| Associated medical issues | Monitoring is recommended, without specified organ complications here. Care is individualized because reported features are limited. Do not infer specific complications from the chromosomal label alone. |
| Diagnostic uncertainty | Phenotype may overlap other developmental conditions. Extreme rarity increases uncertainty about expected findings. Clinical genetics review is appropriate for both. |
Patient education highlights
- HighDiagnosis
A chromosomal test result needs specialist interpretation and does not by itself predict every outcome.
- HighSupport
Both conditions are managed with developmental support and individualized medical monitoring.
- MediumInheritance and family testing
Ask a genetics clinician whether parental testing is useful; recurrence risk is not established here.